Imidazotriazinecarbonitriles useful as kinase inhibitors

US9273057B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Ashok Vinayak Purandare · Pennington, US
• Brian E. Fink · Yardley, US
• Walter Lewis Johnson · Waterbury, US
• Amy C. Hart · Ewing, US
• Liqi He · West Chester, US
• Tram N. Huynh · Pennington, US
• Jennifer Inghrim · Plainsboro, US
• Harold Mastalerz · Guilford, US
• Xiaopeng Sang · Glastonbury, US
• Christine M. Tarby · Lawrenceville, US
• Honghe Wan · Pennington, US
• Wayne Vaccaro · Yardley, US
• Guifen Zhang · Wallingford, US
• Yufen Zhao · Pennington, US
• Kurt Zimmermann · Durham, US
• Yong Zhang · Princeton, US
• Libing Chen · Newtown, US
• Bin Chen · Pennington, US
• John S. Tokarski · Princeton, US
• Ashvinikumar V. Gavai · Princeton Junction, US

Key dates

• Filing date: Jul 12, 2013
• Grant date: Mar 1, 2016
• Expiry date: Jul 12, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/22
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of Formula (I)and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.